Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells—a “back up” approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.